Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anna Melone
Observed names:
A. Melone,
Melone, Anna
Institution:
Bühlmann (Switzerland)
Observed institutions:
University of Basel,
Bühlmann (Switzerland)
ORCID:
0000-0002-7520-1793
Observed ORCID:
0000-0002-7520-1793
OpenAlex ID:
A5047594165
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
2017
·
Florent Beaufils
, Natasa Cmiljanovic
, et al.
·
Journal of Medicinal Chemistry
·
157
Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
2017
·
Thomas Bohnacker
, Andrea E. Prota
, et al.
·
Nature Communications
·
125
PDF
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders
2018
·
Denise Rageot
, Thomas Bohnacker
, et al.
·
Journal of Medicinal Chemistry
·
98
PDF
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
2018
·
Claudia Brandt
, Petra Hillmann
, et al.
·
Neuropharmacology
·
84
( S )-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase
2019
·
Denise Rageot
, Thomas Bohnacker
, et al.
·
Journal of Medicinal Chemistry
·
65
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor
2019
·
Chiara Borsari
, Denise Rageot
, et al.
·
Journal of Medicinal Chemistry
·
50
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety
2019
·
Chiara Borsari
, Denise Rageot
, et al.
·
ACS Medicinal Chemistry Letters
·
44
PDF
4-(Difluoromethyl)-5-(4-((3 R ,5 S )-3,5-dimethylmorpholino)-6-(( R )-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders
2020
·
Chiara Borsari
, Erhan Keles
, et al.
·
Journal of Medicinal Chemistry
·
31
PDF
Separation and detection of all phosphoinositide isomers by ESI-MS
2010
·
Sabine Kiefer
, Johannes Rogger
, et al.
·
Journal of Pharmaceutical and Biomedical Analysis
·
25
Basophil activation test: How many basophils are enough?
2024
·
Léonard Bezinge
, Dominik Vogt
, et al.
·
Allergy
·
7
PDF
Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability
2015
·
Vladimir Cmiljanovic
, Robert A. Ettlin
, et al.
·
Cancer Research
·
6
Abstract 140: Discovery and biological evaluation of PQR530, a highly potent dual pan-PI3K/mTORC1/2 inhibitor
2017
·
Denise Rageot
, Florent Beaufils
, et al.
·
Cancer Research
·
4
Abstract 159: Pharmacological characterization of the selective, orally bioavailable, potent dual PI3K/mTORC1/2 inhibitor PQR530
2017
·
Petra Hillmann
, Denise Rageot
, et al.
·
Cancer Research
·
3
Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor
2015
·
Vladimir Cmiljanovic
, Natasa Cmiljanovic
, et al.
·
Cancer Research
·
3
Development of a Unique Rapid Test to Detect Anti-bodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein: FH-HES Universities of Applied Sciences
2021
·
Larissa Brosi
, Thomas K. Villiger
, et al.
·
CHIMIA International Journal for Chemistry
·
2
PDF
Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas
2015
·
Chiara Tarantelli
, Eugenio Gaudio
, et al.
·
Cancer Research
·
2
Abstract 671: BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition
2015
·
Thomas Bohnacker
, Florent Beaufils
, et al.
·
Cancer Research
·
2
Analytical Validation and Stability Studies for Basophil Activation Test to Meet IVDR Certification.
2024
·
Collin Shaw
, Dominik Vogt
, et al.
·
Journal of Allergy and Clinical Immunology
·
1
Abstract 153: Tricyclic fused pyrimidinopyrrolo-oxazines reveal conformational preferences of morpholine for PI3K hinge region binding
2017
·
Alexander M. Sele
, Denise Rageot
, et al.
·
Cancer Research
·
1
Abstract 393A: Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620
2016
·
Florent Beaufils
, Denise Rageot
, et al.
·
Cancer Research
·
1
Abstract 1336: Structure-activity relationship studies, synthesis, and biological evaluation of PQR620, a highly potent and selective mTORC1/2 inhibitor
2016
·
Florent Beaufils
, Denise Rageot
, et al.
·
Cancer Research
·
1
Analytical performance of the Quantum Blue® fPELA quantitative lateral flow assay for the rapid assessment of fecal pancreatic elastase
2025
·
Leslie Anchling
, Anna Melone
, et al.
·
Pancreatology
Stochastic interpretation of basophil activation test improves diagnostic reliability
2025
·
Jennifer L. Stuart
, Brandon Beloin
, et al.
·
Journal of Immunological Methods
Ab1692 a New, Reliable and Precise High-throughput Serum Calprotectin Assay to Assess the Inflammatory Status of Patients
2023
·
A. Melone
, D. Vogt
, et al.
·
Annals of the Rheumatic Diseases
PDF
Abstract 665: Discovery and preclinical characterization of PQR626: A potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of tuberous sclerosis complex
2020
·
Chiara Borsari
, Erhan Keles
, et al.
·
Cancer Research
Show more works
View as search
Works count:
27
Citation count:
712
H-index:
9
I10-index:
9
Year
Topic
Type